Letrozole: advancing hormone therapy in breast cancer.
Womens Health (Lond)
; 8(6): 611-8, 2012 Nov.
Article
em En
| MEDLINE
| ID: mdl-23181527
ABSTRACT
Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells. Phase III trials in both the advanced and early breast cancer setting have shown an improvement in disease-free survival compared with other compounds, including tamoxifen. Letrozole is well-tolerated, with the main adverse effects reported as hot flushes, arthritis, arthralgia and myalgia, and a trend towards increased risk of fracture.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Triazóis
/
Neoplasias da Mama
/
Antineoplásicos Hormonais
/
Antineoplásicos
/
Nitrilas
Aspecto:
Patient_preference
Limite:
Female
/
Humans
Idioma:
En
Revista:
Womens Health (Lond)
Ano de publicação:
2012
Tipo de documento:
Article